Key result
Elevated high sensitivity cardiac troponin T levels (≥14 ng/L) were independently associated with a 4.0-fold higher risk of hemorrhagic transformation in acute ischemic stroke patients with rheumatic heart disease.
Why the study?
Does elevated hs-cTnT predict hemorrhagic transformation and 3-month mortality in acute ischemic stroke patients with rheumatic heart disease?
Cohort (n=84)
No
Does elevated hs-cTnT predict hemorrhagic transformation and 3-month mortality in acute ischemic stroke patients with rheumatic heart disease?
Odds Ratio: 4.021 (95% CI 1.391–11.625)
Absolute Event Rate: 55.1% vs 25.7%
p-value: p=0.010
Elevated hs-cTnT is an independent predictor of hemorrhagic transformation and 3-month mortality in acute ischemic stroke patients with rheumatic heart disease.
May aid hemorrhagic risk stratification in RHD-related stroke; hypothesis-generating and requires prospective validation.
BACKGROUND AND OBJECTIVE: Elevated levels of high sensitivity cardiac troponin T (hs-cTnT) occur in a substantial proportion of patients with acute ischemic stroke (AIS) and can predict poor outcome and mortality after stroke. Whether elevated hs-cTnT levels can also predict hemorrhagic transformation (HT) or prognosis in AIS patients with rheumatic heart disease (RHD) remains unclear. METHODS: Data from the Chengdu Stroke Registry on consecutive AIS patients with RHD admitted to West China Hospital within 1 month of stroke onset from October 2011 to February 2014 were examined. Clinico-demographic characteristics, HT, functional outcomes and stroke recurrence were compared between patients with elevated hs-cTnT levels (≥14 ng/L) and patients with normal hs-cTnT levels (<14 ng/L). RESULTS: The final analysis involved 84 patients (31 males; mean age, 61.6±12.2 years), of whom serum hs-cTnT levels were elevated in 58.3%. Renal impairment was independently associated with elevated hs-cTnT levels (OR 4.184, 95%CI 1.17 to 15.01, P = 0.028), and patients with elevated hs-cTnT levels were at significantly higher risk of HT, 3-month mortality and 3-month disability/mortality (all P≤0.029). After controlling for age, sex, hypertension, renal impairment and National Institutes of Health Stroke Scale score on admission, the risk of HT and 3-month mortality was, respectively, 4.0- and 5.5-fold higher in patients with elevated hs-cTnT levels than in patients with normal hs-cTnT levels. CONCLUSION: Elevated hs-cTnT levels are independently associated with HT and 3-month mortality in AIS patients with RHD. These results with a small cohort should be verified and extended in large studies.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2016) conducted a cohort in Acute ischemic stroke with rheumatic heart disease (n=84). Elevated hs-cTnT levels (≥14 ng/L) vs. Normal hs-cTnT levels (<14 ng/L) was evaluated on Hemorrhagic transformation (OR 4.021, 95% CI 1.391-11.625, p=0.010). Elevated high sensitivity cardiac troponin T levels (≥14 ng/L) were independently associated with a 4.0-fold higher risk of hemorrhagic transformation in acute ischemic stroke patients with rheumatic heart disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: